Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Cellular and Molecular Biology Letters

Editor-in-Chief: /


IMPACT FACTOR 2016: 1.260
5-year IMPACT FACTOR: 1.506

CiteScore 2016: 1.56

SCImago Journal Rank (SJR) 2016: 0.615
Source Normalized Impact per Paper (SNIP) 2016: 0.470

Online
ISSN
1689-1392
See all formats and pricing
More options …
Volume 14, Issue 2 (Jun 2009)

The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo

Xiao Zhang / Yin-Lin Ge / Run-Hua Tian
Published Online: 2009-03-13 | DOI: https://doi.org/10.2478/s11658-009-0001-9

Abstract

We investigated the effects of RNA interference-mediated silencing of the c-myc gene on celluar proliferation and apoptosis in human colon cancer HT-29 cells in vitro and in vivo. A small interfering RNA (siRNA) targeting c-myc was designed, the DNA template was synthesized, and the siRNA was obtained by in vitro transcription. After siRNA transfection into HT-29 and human neuroblastoma IMR-32 cells with Lipofectamine 2000™, the proliferation of the HT-29 and IMR-32 cells was assessed via 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetry, and Hoechst 33258 staining was used to observe cell apoptosis. Following gene transfer to HT-29 cells, the expression of c-myc mRNA was examined via reverse transcription polymerase chain reaction, and the level of the protein via Western blot assay. Growth curves were constructed and in vivo experiments were performed on nude mice to assess the effects of c-myc silencing on tumor growth. The c-myc expression in the tumor tissue was measured by reverse transcription polymerase chain reaction and subsequently by immunohistochemistry. Our paper demonstrates that the delivery of siRNA directed against c-myc not only efficiently down-regulated the expression of c-myc, inhibited the proliferation of HT-29 cells and induced apoptosis in vitro, but also suppressed the growth of colon cancer cells in vivo.

Keywords: c-myc; Cell proliferation; HT-29; siRNA

  • [1] Ahmed, F.E. Molecular markers that predict response to colon cancer therapy. Expert Rev. Mol. Diagn. 5 (2005) 353–375. http://dx.doi.org/10.1586/14737159.5.3.353CrossrefGoogle Scholar

  • [2] Grady, W.M. and Carethers, J.M. Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis. Gastroenterology 135 (2008) 1079–1099. http://dx.doi.org/10.1053/j.gastro.2008.07.076Web of ScienceCrossrefGoogle Scholar

  • [3] Grandori, C., Cowley, S.M., James, L.P. and Eisenman, R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16 (2000) 653–699. http://dx.doi.org/10.1146/annurev.cellbio.16.1.653CrossrefGoogle Scholar

  • [4] Bondi, J., Bukholm, G., Nesland, J.M. and Bukholm, I.R. Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112 (2004) 49–56. http://dx.doi.org/10.1111/j.1600-0463.2004.apm1120109.xGoogle Scholar

  • [5] Csontos, Z., Nádasi, E., Csejtey, A., Illényi, L., Kassai, M., Lukács, L., Kelemen, D., Kvarda, A. Zólyomi, A., Horváth, O.P. and Ember, I. Oncogene and tumor suppressor gene expression changes in the peripheral blood leukocytes of patients with colorectal cancer. Tumori 94 (2008) 79–82. Google Scholar

  • [6] Dang, C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19 (1999) 1–11. Google Scholar

  • [7] Hongxing, Z., Nancai, Y., Wen, S., Guofu, H., Yanxia, W., Hanju, H., Qian, L., Wei, M., Yandong, Y. and Hao, H. Depletion of c-Myc inhibits human colon cancer colo 320 cells’ growth. Cancer Biother. Radiopharm. 23 (2008) 229–237. http://dx.doi.org/10.1089/cbr.2007.0441Web of ScienceCrossrefGoogle Scholar

  • [8] Schwab, M., Reynders, V., Loitsch, S., Shastri, Y.M., Steinhilber, D., Schröder, O. and Stein, J. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29 (2008) 1407–1414. http://dx.doi.org/10.1093/carcin/bgn118CrossrefWeb of ScienceGoogle Scholar

  • [9] Wilkins, J.A. and Sansom, O.J. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res. 68 (2008) 4963–4966. http://dx.doi.org/10.1158/0008-5472.CAN-07-5558Web of ScienceCrossrefGoogle Scholar

  • [10] Colnot, S., Niwa-Kawakita, M., Hamard, G., Godard, C., Le Plenier, S., Houbron, C., Romagnolo, B., Berrebi, D., Giovannini, M. and Perret, C. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab. Invest. 84 (2004) 1619–1630. http://dx.doi.org/10.1038/labinvest.3700180CrossrefGoogle Scholar

  • [11] Al-Kuraya, K., Novotny, H., Bavi, P., Siraj, A.K., Uddin, S., Ezzat, A., Sanea, N.A., Al-Dayel, F., Al-Mana, H., Sheikh, S.S., Mirlacher, M., Tapia, C., Simon, R., Sauter, G., Terracciano, L. and Tornillo, L. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 60 (2007) 768–772. http://dx.doi.org/10.1136/jcp.2006.038281CrossrefGoogle Scholar

  • [12] Stewart, J., Evan, G., Watson, J. and Sikora, K. Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br. J. Cancer 53 (1986) 1–6. Google Scholar

  • [13] Hannon, G.J. RNA interference. Nature 418 (2002) 244–251. http://dx.doi.org/10.1038/418244aCrossrefGoogle Scholar

  • [14] Watson, P.H., Pon, R.T. and Shiu, R.P.C. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51 (1991) 3996–4000. Google Scholar

  • [15] Hong, J., Zhao, Y. and Huang, W. Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. Biochem. Biophys. Res. Commun. 348 (2006) 600–605. http://dx.doi.org/10.1016/j.bbrc.2006.07.107CrossrefGoogle Scholar

  • [16] Liao, D.J. and Dickson, R.B. c-Myc in breast cancer. Endocr. Relat. Cancer 7 (2000) 143–164. http://dx.doi.org/10.1677/erc.0.0070143CrossrefGoogle Scholar

  • [17] Kruszewski, W., Kowara, R., Rzepko, R., Warezak, C., Zieliński, J., Gryglewski, G., Kopacz, A., Jastrzebski, T. and Pawełczyk, T. K-RAS point mutation, and amplification of C-MYC and C-ERBB2 in colon adenocarcinoma. Folia Histochem. Cytobiol. 42 (2004) 173–179. Google Scholar

  • [18] Nagy, B., Szendroi, A. and Romics, I. Overexpression of CD24, c-myc and Phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol. Oncol. Res. 2008. Web of ScienceGoogle Scholar

  • [19] Steiner, M.S., Anthony, C.T., Lu, Y. and Holt, J.T. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Ther. 9 (1998) 747–755. http://dx.doi.org/10.1089/hum.1998.9.5-747CrossrefGoogle Scholar

  • [20] Bressin, C., Bourgarel-Rey, V., Carré, M., Pourroy, B., Arango, D., Braguer, D. and Barra, Y. Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anticancer Drugs 17 (2006) 181–187. http://dx.doi.org/10.1097/00001813-200602000-00009CrossrefGoogle Scholar

  • [21] Zhao, H.Y., Ooyama, A., Yamamoto, M., Ikeda, R., Haraguchi, M., Tabata, S., Furukawa, T., Che, X.F., Iwashita, K.I., Oka, T., Fukushima, M., Nakagawa, M., Ono, M., Kuwano, M. and Akiyama, S.I. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett. 270 (2008) 156–163. http://dx.doi.org/10.1016/j.canlet.2008.04.045CrossrefGoogle Scholar

  • [22] Bertrand, J.R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A. and Malvy, C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296 (2002) 1000–1004. http://dx.doi.org/10.1016/S0006-291X(02)02013-2CrossrefGoogle Scholar

  • [23] Prendergast, G.C. Mechanisms of apoptosis by c-Myc. Oncogene 1 (1999) 2967–2987. http://dx.doi.org/10.1038/sj.onc.1202727CrossrefGoogle Scholar

  • [24] Wang, Y.H., Liu, S., Zhang, G., Zhou, C.Q., Zhu, H.X., Zhou, X.B., Quan, L.P., Bai, J.F. and Xu, N.Z. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7 (2005) 220–228. http://dx.doi.org/10.1186/bcr975CrossrefGoogle Scholar

About the article

Published Online: 2009-03-13

Published in Print: 2009-06-01


Citation Information: Cellular and Molecular Biology Letters, ISSN (Online) 1689-1392, DOI: https://doi.org/10.2478/s11658-009-0001-9.

Export Citation

© 2009 University of Wrocław, Poland. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jian-Xia Xu, Wei Xiong, Zhen Zeng, Yi Tang, Ya-Lan Wang, Ming Xiao, Ming Li, Qing Shu Li, Guang-Lin Song, and Jing Kuang
Molecular Medicine Reports, 2017, Volume 15, Number 3, Page 1222
[2]
Eun-Jung Park, Mayuramas Sang-Ngern, Leng Chee Chang, and John M. Pezzuto
Molecular Nutrition & Food Research, 2016, Volume 60, Number 6, Page 1482
[3]
Hyeon-Geun Ji, Juan-Yu Piao, Su-Jung Kim, Do-Hee Kim, Ha-Na Lee, Hye-Kyung Na, and Young-Joon Surh
Molecular Nutrition & Food Research, 2016, Volume 60, Number 6, Page 1448
[4]
Rajamani Barathidasan, Rajveer Singh Pawaiya, Ram Bahal Rai, and Kuldeep Dhama
Asian Pacific Journal of Cancer Prevention, 2013, Volume 14, Number 8, Page 4883
[5]
R. K. Cruz-Bravo, R. G. Guevara-González, M. Ramos-Gómez, B. D. Oomah, P. Wiersma, R. Campos-Vega, and G. Loarca-Piña
Genes & Nutrition, 2014, Volume 9, Number 1
[6]
Jing Zheng, Jian-Da Hu, Ying-Yu Chen, Bu-Yuan Chen, Yi Huang, Zhi Hong Zheng, and Ting-Bo Liu
Asian Pacific Journal of Cancer Prevention, 2012, Volume 13, Number 4, Page 1119
[7]
Ziyad Binkhathlan and Aws Alshamsan
Therapeutic Delivery, 2012, Volume 3, Number 9, Page 1117
[8]
Markus Benfer and Thomas Kissel
European Journal of Pharmaceutics and Biopharmaceutics, 2012, Volume 80, Number 2, Page 247
[9]
Iori Takigami, Takatoshi Ohno, Yukio Kitade, Akira Hara, Akihito Nagano, Gou Kawai, Mitsuru Saitou, Aya Matsuhashi, Kazunari Yamada, and Katsuji Shimizu
International Journal of Cancer, 2011, Volume 128, Number 1, Page 216
[10]
Y. Touchefeu, K. J. Harrington, J. P. Galmiche, and G. Vassaux
Alimentary Pharmacology & Therapeutics, 2010, Volume 32, Number 8, Page 953
[11]
Connor Phalon, Donald D. Rao, and John Nemunaitis
Expert Reviews in Molecular Medicine, 2010, Volume 12
[12]
G Munkácsy, R Abdul-Ghani, Z Mihály, B Tegze, O Tchernitsa, P Surowiak, R Schäfer, and B Györffy
British Journal of Cancer, 2010, Volume 102, Number 2, Page 361
[13]
Joshua M. Uronis and David W. Threadgill
Mammalian Genome, 2009, Volume 20, Number 5, Page 261

Comments (0)

Please log in or register to comment.
Log in